Literature DB >> 11167806

Glucose transport regulation by p210 Bcr-Abl in a chronic myeloid leukaemia model.

J Bentley1, I Walker, E McIntosh, A D Whetton, P J Owen-Lynch, S A Baldwin.   

Abstract

The regulation of nutrient transport by both cytokines and oncogenes has been linked to haemopoietic cell survival. In this study, we found that activation of Bcr--Abl protein tyrosine kinase was associated with the stimulation of glucose transport in the multipotent haemopoietic cell line FDCP-mix, a cell model for chronic-phase chronic myeloid leukaemia (CML). Bcr--Abl upregulation of glucose transport was mediated by phosphatidylinositol-3-kinase. The observation that Bcr--Abl can regulate glucose transport in a CML cell model raises the possibility that glucose transport regulation may have a role to play in the aberrant survival of stem cells in the chronic phase of CML.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11167806     DOI: 10.1046/j.1365-2141.2001.02428.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  13 in total

1.  Structure guided design and synthesis of furyl thiazolidinedione derivatives as inhibitors of GLUT 1 and GLUT 4, and evaluation of their anti-leukemic potential.

Authors:  Kalpana Tilekar; Neha Upadhyay; Jessica D Hess; Lucasantiago Henze Macias; Piotr Mrowka; Renato J Aguilera; Franz-Josef Meyer-Almes; Cristina V Iancu; Jun-Yong Choe; C S Ramaa
Journal:  Eur J Med Chem       Date:  2020-07-02       Impact factor: 6.514

2.  Glycogen synthase kinase 3alpha and 3beta mediate a glucose-sensitive antiapoptotic signaling pathway to stabilize Mcl-1.

Authors:  Yuxing Zhao; Brian J Altman; Jonathan L Coloff; Catherine E Herman; Sarah R Jacobs; Heather L Wieman; Jessica A Wofford; Leah N Dimascio; Olga Ilkayeva; Ameeta Kelekar; Tannishtha Reya; Jeffrey C Rathmell
Journal:  Mol Cell Biol       Date:  2007-03-19       Impact factor: 4.272

Review 3.  Metabolic underpinnings of leukemia pathology and treatment.

Authors:  Travis Nemkov; Angelo D'Alessandro; Julie A Reisz
Journal:  Cancer Rep (Hoboken)       Date:  2018-10-07

4.  Mechanisms and methods in glucose metabolism and cell death.

Authors:  Yuxing Zhao; Heather L Wieman; Sarah R Jacobs; Jeffrey C Rathmell
Journal:  Methods Enzymol       Date:  2008       Impact factor: 1.600

5.  Symptomatic hypoglycemia during imatinib mesylate in a non-diabetic female patient with gastrointestinal stromal tumor.

Authors:  M Haap; B Gallwitz; C Thamer; K Müssig; H-U Häring; L Kanz; J T Hartmann
Journal:  J Endocrinol Invest       Date:  2007-09       Impact factor: 4.256

6.  New roles for pyruvate kinase M2: working out the Warburg effect.

Authors:  Emily C Ferguson; Jeffrey C Rathmell
Journal:  Trends Biochem Sci       Date:  2008-07-04       Impact factor: 13.807

7.  Lyn regulates creatine uptake in an imatinib-resistant CML cell line.

Authors:  Denis O Okumu; Lucas J Aponte-Collazo; Brian J Dewar; Nathan J Cox; Michael P East; Katherine Tech; Ian M McDonald; Andrey P Tikunov; Ekhson Holmuhamedov; Jeffrey M Macdonald; Lee M Graves
Journal:  Biochim Biophys Acta Gen Subj       Date:  2019-12-24       Impact factor: 3.770

8.  Exploiting mitochondrial dysfunction for effective elimination of imatinib-resistant leukemic cells.

Authors:  Jérome Kluza; Manel Jendoubi; Caroline Ballot; Abir Dammak; Aurélie Jonneaux; Thierry Idziorek; Sami Joha; Véronique Dauphin; Myriam Malet-Martino; Stéphane Balayssac; Patrice Maboudou; Gilbert Briand; Pierre Formstecher; Bruno Quesnel; Philippe Marchetti
Journal:  PLoS One       Date:  2011-07-18       Impact factor: 3.240

9.  Imatinib mesylate reduces endoplasmic reticulum stress and induces remission of diabetes in db/db mice.

Authors:  Myoung Sook Han; Kun Wook Chung; Hyae Gyeong Cheon; Sang Dal Rhee; Chang-Hwan Yoon; Moon-Kyu Lee; Kwang-Won Kim; Myung-Shik Lee
Journal:  Diabetes       Date:  2009-02       Impact factor: 9.461

10.  Evaluation of 2-deoxy-D-glucose as a chemotherapeutic agent: mechanism of cell death.

Authors:  R L Aft; F W Zhang; D Gius
Journal:  Br J Cancer       Date:  2002-09-23       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.